Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 229

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help?

From Sonora to Big Pharma: Kimon de Greef Traces the Strange Rise of 5-MeO-DMT

Psychedelic Alpha Crossword: Summer 2026

Psilocybin Trial in Veterans With Treatment-Resistant PTSD Reports 75% Remission at One Month

Psychedelic Policy Briefing: Week of July 27th, 2026

Braxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy...

U.S. FDA Approves Nova Mentis Orphan Drug Application

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

Cybin Hosting Research and Development Briefing on November 8, 2021

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct...

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results...

PT269 – Adam Strauss – Comedy, OCD, and The Mushroom Cure

Psychedelic Research Bulletin: October 2021

The Compounds in Psychedelic Cacti

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort...

Load more

EDITOR PICKS

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly;...

From Sonora to Big Pharma: Kimon de Greef Traces the Strange...

Psychedelic Alpha Crossword: Summer 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©